open access

Vol 4, Supp. B (2013)
Case report
Published online: 2013-10-25
Get Citation

Successful nilotinib therapy in the patient with chronic myelogenous leukemia with secondary resistance to imatinib

Ilona Seferyńska, Krzysztof Warzocha

open access

Vol 4, Supp. B (2013)
CASE REPORTS
Published online: 2013-10-25

Abstract

Imatinib (IM) failure and/or intolerance in the fi rst line treatment of patients with chronic myelogenous leukemia (CML) is an indication to change strategy into the higher doses of IM or second generation tyrosine kinase inhibitors (TKI). The main cause of treatment failure is BCR-ABL1 mutation and patient’s nonadherence. The patient presented in this case was initially treated with standard dose of IM and after 3 months complete hematologic response (CHR) and complete cytogenetic response (CCyR) were achieved. After 6 months since then cytogenetic failure was observed. The presence of BCR-ABL1 mutation was revealed. Then, therapy with nilotinib was introduced and CHR, CCyR and major molecular response were again achieved.

Abstract

Imatinib (IM) failure and/or intolerance in the fi rst line treatment of patients with chronic myelogenous leukemia (CML) is an indication to change strategy into the higher doses of IM or second generation tyrosine kinase inhibitors (TKI). The main cause of treatment failure is BCR-ABL1 mutation and patient’s nonadherence. The patient presented in this case was initially treated with standard dose of IM and after 3 months complete hematologic response (CHR) and complete cytogenetic response (CCyR) were achieved. After 6 months since then cytogenetic failure was observed. The presence of BCR-ABL1 mutation was revealed. Then, therapy with nilotinib was introduced and CHR, CCyR and major molecular response were again achieved.
Get Citation

Keywords

chronic myelogenous leukemia, BCR-ABL1 gene mutations, treatment failure, imatinib, nilotinib

About this article
Title

Successful nilotinib therapy in the patient with chronic myelogenous leukemia with secondary resistance to imatinib

Journal

Hematology in Clinical Practice

Issue

Vol 4, Supp. B (2013)

Article type

Case report

Pages

7-11

Published online

2013-10-25

Keywords

chronic myelogenous leukemia
BCR-ABL1 gene mutations
treatment failure
imatinib
nilotinib

Authors

Ilona Seferyńska
Krzysztof Warzocha

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.